nvolve risks and uncertainties. In
some cases, forward-looking statements are identified by words such as
"believe," "anticipate," "expect," "intend," "plan," "potential,"
"estimate," "will," "may," "predict," "should," "could," "would" and
similar expressions. You should not place undue reliance on these
forward-looking statements, which speak only as of the date of this
announcement. All of these forward-looking statements are based on
information available to us at this time. Actual results could differ from
those projected in these forward-looking statements as a result of many
factors, including those identified in the sections titled "Risk Factors,"
in our Registration Statement on Form S-3 as filed with the Securities and
Exchange Commission on October 17, 2008, and in our "Management's
Discussion and Analysis of Financial Condition and Results of Operations"
and elsewhere in our Annual Report on Form 10-K for the year ended Dec. 31,
2007 and in similar disclosures made by us from time to time in our other
filings with the Securities and Exchange Commission. We undertake no
obligation to update forward-looking statements, whether as a result of new
information, future events or otherwise. You are advised, however, to
consult any further disclosures we make on related subjects in our filings
with the Securities and Exchange Commission. MiddleBrook, MiddleBrook
Pharmaceuticals (stylized), MiddleBrook Pharmaceuticals, Inc., Pulsys,
Moxatag and Keflex are our trademarks and have been registered in the U.S.
Patent and Trademark Office or are the subject of pending U.S. trademark
applications. Each of the other trademarks, tradenames or services marks
appearing in this document belongs to its respective holder.
MiddleBrook Pharmaceuticals, Inc.
Consolidated Statements of Income
(Amounts in thousands, except per share amounts)
For the Three Months For t
Page: 1 2 3 4 5 6 7 8 9 10 11 Related medicine news :1
|SOURCE MiddleBrook Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved
. MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management2
. MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results3
. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity4
. MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process5
. MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results6
. MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results7
. MiddleBrook to Webcast Management Presentation at the 10th Annual Rodman & Renshaw Healthcare Conference8
. MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Third Quarter 2008 Financial Results9
. MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates10
. MiddleBrook Pharmaceuticals Announces Orange Book Listing of Moxatag(TM) Patents11
. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference